First attempt to validate the gSG6-P1 salivary peptide as an immuno-epidemiological tool for evaluating human exposure to Anopheles funestus bites.

@article{Poinsignon2010FirstAT,
  title={First attempt to validate the gSG6-P1 salivary peptide as an immuno-epidemiological tool for evaluating human exposure to Anopheles funestus bites.},
  author={Anne Poinsignon and Badara Samb and Souleymane Doucour{\'e} and Papa-Makhtar Drame and Jean Biram Sarr and Cheikh Saya Sow and Sylvie Corn{\'e}lie and Sophie Maiga and Cheikh Thiam and François Rogerie and Sohidou Guindo and Emmanuel Hermann and François Simondon and Ibrahima Dia and Gilles Riveau and Lassana Konat{\'e} and Franck J Remoue},
  journal={Tropical medicine & international health : TM & IH},
  year={2010},
  volume={15 10},
  pages={1198-203}
}
SUMMARY OBJECTIVE The development of a biomarker of exposure based on the evaluation of the human antibody response specific to Anopheles salivary proteins seems promising in improving malaria control. The IgG response specific to the gSG6-P1 peptide has already been validated as a biomarker of An. gambiae exposure. This study represents a first attempt to validate the gSG6-P1 peptide as an epidemiological tool evaluating exposure to An. funestus bites, the second main malaria vector in sub… CONTINUE READING